phkineticaФармакокинетика и ФармакодинамикаPharmacokinetics and Pharmacodynamics2587-78362686-8830ООО «Издательство ОКИ»10.37489/2587-7836-2021-1-3-13phkinetica-266Research ArticleКЛИНИЧЕСКАЯ ФАРМАКОКИНЕТИКАCLINICAL PHARMACOKINETICSОпределение сывороточных/плазменных концентраций психотропных препаратов в терапевтическом лекарственном мониторингеDetermination of Serum/Plasma Concentrations of Psychotropic Drugs in Therapeutic Drug Monitoringhttps://orcid.org/0000-0003-4950-5336МирошниченкоИ. И.MiroshnichenkoI. I.

Мирошниченко Игорь Иванович, д. м. н., зав. лабораторией фармакокинетики

SPIN-код: 4117-9703

Москва 

Miroshnichenko Igor I., Dr. Sci. (Med.), Head of pharmacokinetics laboratory

SPIN code: 4117-9703

Moscow 

igormir@psychiatry.ruhttps://orcid.org/0000-0002-4429-4114БаймееваН. В.BaymeevaN. V.

Баймеева Наталья Викторовна, н. с. лаборатории фармакокинетики

SPIN-код: 7080-2142

Москва 

Baymeeva Nalalia V., Researcher of pharmacokinetics laboratory

SPIN code: 7080-2142

Moscow 

baymeeva_n@mail.ruhttps://orcid.org/0000-0002-9682-4623ПлатоваА. И.PlatovaA. I.

Платова Ангелина Игоревна, н. с. лаборатории фармакокинетики

SPIN-код: 6656-2194

Москва 

Platova Angelina I., Researcher of pharmacokinetics laboratory

SPIN code: 6656-2194

Moscow 

platova@psychiatry.ruФГБНУ «Научный центр психического здоровья»РоссияFSBSI «Mental Health Research Center»Russian Federation20212709202101313Copyright © Мирошниченко И.И., Баймеева Н.В., Платова А.И., 20212021Мирошниченко И.И., Баймеева Н.В., Платова А.И.Miroshnichenko I.I., Baymeeva N.V., Platova A.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacokinetica.ru/jour/article/view/266

В статье рассмотрены основные методологические приёмы проведения терапевтического лекарственного мониторинга (ТЛМ) психотропных препаратов. Описаны аналитические методы, позволяющие выполнять эти исследования. Приведена интерпретация, примеры и краткие результаты 2 исследований ТЛМ антипсихотических препаратов, выполненных на базе ФГБНУ НЦПЗ и Психиатрической больницы № 14 г. Москвы.

The article considers the main methodological methods of therapeutic drug monitoring (TDM) of psychotropic drugs. Analytical methods that allow performing these studies have been described. It has been given the interpretation, examples and brief results of two studies of TDM of antipsychotic drugs made in FSBSI “Mental Health Research Center” and Psychiatric hospital No.14 in Moscow.

терапевтический лекарственный мониторингантипсихотические препаратыантидепрессантыtherapeutic drug monitoringantipsychotic drugsantidepressantsReferencesBuclin T, Thoma Y, Widmer N, Pascal A, Monia G, Chantal C, Laurent A. Decosterd. The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated with Imatinib. Front Pharmacol. 2020; 11:177. DOI: 10.3389/fphar.2020.00177.Buclin T, Thoma Y, Widmer N, Pascal A, Monia G, Chantal C, Laurent A. Decosterd. The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated with Imatinib. Front Pharmacol. 2020; 11:177. DOI: 10.3389/fphar.2020.00177.Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry. 2018;51(1-02):9–62. DOI: 10.1055/s-0043-116492.Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry. 2018;51(1-02):9–62. DOI: 10.1055/s-0043-116492.Jönsson AK, Spigset O, Reis MA. Compilation of serum concentrations of 12 antipsychotic drugs in a therapeutic drug monitoring setting. Ther Drug Monit. 2019;41(3):348–356. DOI: 10.1097/FTD.0000000000000585.Jönsson AK, Spigset O, Reis MA. Compilation of serum concentrations of 12 antipsychotic drugs in a therapeutic drug monitoring setting. Ther Drug Monit. 2019;41(3):348–356. DOI: 10.1097/FTD.0000000000000585.Wyska E. Pharmacokinetic considerations for current state-of-the-art antidepressants. Expert Opinion on Drug Metabolism & Toxicology. 2019;15(10):831–847. DOI: 10.1080/17425255.2019.1669560.Wyska E. Pharmacokinetic considerations for current state-of-the-art antidepressants. Expert Opinion on Drug Metabolism & Toxicology. 2019;15(10):831–847. DOI: 10.1080/17425255.2019.1669560.Stanke-Labesque F, Gautier-Veyret E, Chhun S, Guilhaumou R. Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment. Pharmacol Ther. 2020 Nov; 215:107627. DOI: 10.1016/j.pharmthera.2020.107627.Stanke-Labesque F, Gautier-Veyret E, Chhun S, Guilhaumou R. Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment. Pharmacol Ther. 2020 Nov; 215:107627. DOI: 10.1016/j.pharmthera.2020.107627.Legare N, Gregoire CA, De Benedicts L, Dumais A. Increasing the clozapine: norclozapine ratio with co-administration of fluvoxamine to enhance efficacy and minimize side effects of clozapine therapy. Med Hypotheses. 2013;80(6):689–691. DOI: 10.1016/j.mehy.2012.12.024.Legare N, Gregoire CA, De Benedicts L, Dumais A. Increasing the clozapine: norclozapine ratio with co-administration of fluvoxamine to enhance efficacy and minimize side effects of clozapine therapy. Med Hypotheses. 2013;80(6):689–691. DOI: 10.1016/j.mehy.2012.12.024.Sutherland JJ, Morrison RD, Daniels JS, Milne SB, Ryan TP. Managing psychotropic medications in complex, real-world patients using comprehensive therapeutic drug monitoring. ACS Chem. Neurosci. 2017; 8: 1641–1644. DOI: 10.1021/acschemneuro.7b00209.Sutherland JJ, Morrison RD, Daniels JS, Milne SB, Ryan TP. Managing psychotropic medications in complex, real-world patients using comprehensive therapeutic drug monitoring. ACS Chem. Neurosci. 2017; 8: 1641–1644. DOI: 10.1021/acschemneuro.7b00209.Мирошниченко ИИ. Рациональное дозирование и мониторинг лекарственных средств. – М.: Медицинское информационное агентство. 2011. 416 c. [Miroshnichenko II. Racional'noe dozirovanie i monitoring lekarstvennyh sredstv. Moscow: Medicinskoe informacionnoe agentstvo. 2011. (In Russ).].Мирошниченко ИИ. Рациональное дозирование и мониторинг лекарственных средств. – М.: Медицинское информационное агентство. 2011. 416 c. [Miroshnichenko II. Racional'noe dozirovanie i monitoring lekarstvennyh sredstv. Moscow: Medicinskoe informacionnoe agentstvo. 2011. (In Russ).].Ooba N, Tsutsumi D, Kobayashi N, Hidaka S, Hayashi H, Obara T, Satoh M, Kubota K, Fukuoka N. Prevalence of therapeutic drug monitoring for lithium and the impact of regulatory warnings: analysis using japanese claims database. Ther Drug Monit. 2018;40(2):252–256. DOI: 10.1097/FTD.0000000000000483.Ooba N, Tsutsumi D, Kobayashi N, Hidaka S, Hayashi H, Obara T, Satoh M, Kubota K, Fukuoka N. Prevalence of therapeutic drug monitoring for lithium and the impact of regulatory warnings: analysis using japanese claims database. Ther Drug Monit. 2018;40(2):252–256. DOI: 10.1097/FTD.0000000000000483.Gervasini G., Benítez J, Carrillo JA. Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. Eur J Clin Pharmacol. 2010;66(8):755–774. DOI: 10.1007/s00228-010-0857-7.Gervasini G., Benítez J, Carrillo JA. Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. Eur J Clin Pharmacol. 2010;66(8):755–774. DOI: 10.1007/s00228-010-0857-7.Müller MJ, Dragicevic A, Fric M, Gaertner I, Grasmäder K, Härtter S, Hermann E, Kuss HJ, Laux G, Oehl W, Rao ML, Rollmann N, Weigmann H, Weber-Labonte M, Hiemke C. Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinical conditions? Pharmacopsychiatry. 2003;36(3):98–104. DOI: 10.1055/s-2003-39983.Müller MJ, Dragicevic A, Fric M, Gaertner I, Grasmäder K, Härtter S, Hermann E, Kuss HJ, Laux G, Oehl W, Rao ML, Rollmann N, Weigmann H, Weber-Labonte M, Hiemke C. Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinical conditions? Pharmacopsychiatry. 2003;36(3):98–104. DOI: 10.1055/s-2003-39983.Brandhorst G, Oellerich M, Maine G, Taylor P, Veen G, Wallemacq P. Liquid chromatography–tandem mass spectrometry or automated immunoassays: what are the future trends in therapeutic drug monitoring? Clin Chem. 2012;58(5):821–825. DOI: 10.1373/clinchem.2011.167189.Brandhorst G, Oellerich M, Maine G, Taylor P, Veen G, Wallemacq P. Liquid chromatography–tandem mass spectrometry or automated immunoassays: what are the future trends in therapeutic drug monitoring? Clin Chem. 2012;58(5):821–825. DOI: 10.1373/clinchem.2011.167189.Tuzimski T, Petruczynik A. Review of chromatographic methods coupled with modern detection techniques applied in the therapeutic drugs monitoring (TDM). Molecules. 2020;25(17):4026. DOI: 10.3390/molecules25174026.Tuzimski T, Petruczynik A. Review of chromatographic methods coupled with modern detection techniques applied in the therapeutic drugs monitoring (TDM). Molecules. 2020;25(17):4026. DOI: 10.3390/molecules25174026.Miroshnichenko II., Baymeeva NV. Simultaneous determination of antipsychotic drugs and their active metabolites by LC-MS-MS and its application to therapeutic drug monitoring. J Chromatogr Sci. 2018;56(6): 510–517. DOI: 10.1093/chromsci/bmy024.Miroshnichenko II., Baymeeva NV. Simultaneous determination of antipsychotic drugs and their active metabolites by LC-MS-MS and its application to therapeutic drug monitoring. J Chromatogr Sci. 2018;56(6): 510–517. DOI: 10.1093/chromsci/bmy024.Srinivas NR. Should commonly prescribed drugs be avoided as internal standard choices in new assays for clinical samples? Bioanalysis. 2016; 8(7):607–610. DOI: 10.4155/bio.16.21Srinivas NR. Should commonly prescribed drugs be avoided as internal standard choices in new assays for clinical samples? Bioanalysis. 2016; 8(7):607–610. DOI: 10.4155/bio.16.21Fuchs A, Chantal C, Thoma Y, Buclin T, Widmer N. Benchmarking therapeutic drug monitoring software: a review of available computer tools. Clin Pharmacokinet. 2013;52(1):9–22. DOI: 10.1007/s40262-012-0020-y.Fuchs A, Chantal C, Thoma Y, Buclin T, Widmer N. Benchmarking therapeutic drug monitoring software: a review of available computer tools. Clin Pharmacokinet. 2013;52(1):9–22. DOI: 10.1007/s40262-012-0020-y.

The authors declare that there are no conflicts of interest present.